[ad_1]
Celsion is conducting a clinical study of a new immunotherapy, GEN-1, in ovarian cancer. Women with newly diagnosed ovarian cancer are encouraged to speak with their doctors and visit http://www.ovariancancerstudy.com to learn more.
NEW YORK, March 31, 2022 /PRNewswire-PRWeb/ –Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has partnered with Mediaplanet to generate national awareness of the company’s ongoing clinical study in ovarian cancer, as well as to highlight the importance for patients with cancer to join a clinical study.
Celsion is conducting a national clinical research study of a new immunotherapy, GEN-1, in patients with newly diagnosed ovarian cancer. The company has partnered with Mediaplanet to increase awareness of ovarian cancer research and to invite women with ovarian cancer to learn more about the Company’s OVATION 2 study. The study is being conducted at major cancer institutions throughout the United States and in Montreal, Canada and is currently enrolling patients. Women with newly diagnosed ovarian cancer are encouraged to visit http://www.ovariancancerstudy.com to learn more about the OVATION 2 study and to consider entering this trial.
“Celsion Corporation…
Full story available on Benzinga.com
[ad_2]
Source link
